Twist Bioscience Corp. Stock News

Twist Bioscience Corp (NASDAQ: TWST) and Eleven Therapeutics have created a replicon tool that could be used for studying viral genome replication, antiviral drug screening, and vaccine & therapeut

Twist Bioscience's (TWST) CEO Emily Leproust on Q1 2022 Results - Earnings Call Transcript

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its sili

Twist Bioscience Corp  TWST reported a 49.2% Y/Y increase in its Q1 FY22 revenues to $42.02 million, beating the Wall Street estimate of $38.33 million and the management expectation of $37 million

Twist Bioscience (TWST) delivered earnings and revenue surprises of 15.74% and 10.48%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Twist Bioscience (NASDAQ:TWST) is scheduled to announce Q1 earnings results on Friday, February 4th, before market open.The consensus EPS Estimate is -$1.06 (-47.2% Y/Y) and the

The stock price of Twist Bioscience Corp (NASDAQ: TWST) increased by 4.93% in the most recent trading session. This is why it happened.

Twist Bioscience Corp (TWST) shares closed today 13.9% higher than it did at the end of yesterday. The stock is currently down 32.6% year-to-date, down 68.3% over the past 12 months, and up 272.7% over the past five years. Today, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 1.8%. Trading Activity Shares traded as high as $59.77 and as low as $49.21 this week.Shares closed 70.6% below its 52-week high and 22.2% above its 52-week low.Trading volume this week was 4.8% higher than the 10-day average and 24.2% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.6. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 16.9% The company's stock price performance over the past 12 months beats the peer average by -4.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower. Johnson & Johnson (NYSE: JNJ) got the ball rolling on large-cap biopharma earnings, with

Twist Bioscience had an abysmal 2021 year in the market, but their DNA synthesizing technology has them poised for a major rebound. The post-Covid biotech market is positioned for an overall increase

They're risky. But they could also be huge winners.

They're risky. But they could also be huge winners.

Twist Bioscience (TWST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Twist Bioscience (TWST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.